{"DataElement":{"publicId":"13381583","version":"1","preferredName":"Biospecimen Histologic Grade Type","preferredDefinition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type based on microscopic findings.","longName":"6953488v1.00:13336620v1.00","context":"Pediatric Cancer","contextVersion":"1","DataElementConcept":{"publicId":"6953488","version":"1","preferredName":"Biospecimen Histologic Grade","preferredDefinition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","longName":"2859635v1.0:2427327v1.0","context":"MCL","contextVersion":"1","ObjectClass":{"publicId":"2859635","version":"1","preferredName":"Biospecimen","preferredDefinition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.","longName":"C70699","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biospecimen","conceptCode":"C70699","definition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66832E51-39F3-1736-E040-BB89AD4349FB","latestVersionIndicator":"Yes","beginDate":"2009-04-01","endDate":null,"createdBy":"UMLLOADER_TAVERNA","dateCreated":"2009-04-01","modifiedBy":"ONEDATA","dateModified":"2009-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2427327","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"C18000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05116195-EBA8-7341-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-09","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-09","modifiedBy":"ONEDATA","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008576","version":"1","preferredName":"Data Source","preferredDefinition":"the source of patient information.","longName":"DATA_SOURCE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB881FE7-E125-2545-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-04-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-04-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MCL:Molecular and Cellular Characterization of Screened Lesions","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"93DE137A-3B72-7A33-E053-F662850A2F8A","latestVersionIndicator":"Yes","beginDate":"2019-10-01","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-10-01","modifiedBy":"COLBERTM","dateModified":"2022-02-28","changeDescription":"2/28/22 mr Released per SME.   9/14/21 jk revised for use in PCA Lung CDEs.  10/1/19 jk created for MCL LabCas PCA-Genomic pilot.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"13336620","version":"1","preferredName":"Histologic Grade Type","preferredDefinition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems._Something distinguishable as an identifiable class based on common qualities.","longName":"13336620v1.00","context":"Pediatric Cancer","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"FNCLCC, Grade GX","valueDescription":null,"ValueMeaning":{"publicId":"7653577","version":"1","preferredName":"FNCLCC Sarcoma Grade GX Grade cannot be assessed","longName":"7653577","preferredDefinition":"A sarcoma with a GX  grade that cannot be assessed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FNCLCC Sarcoma Grade GX Grade cannot be assessed","conceptCode":"C160730","definition":"A sarcoma with a GX  grade that cannot be assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C223A6E9-6503-1AAB-E053-4EBD850A3FD4","latestVersionIndicator":"Yes","beginDate":"2021-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-12","modifiedBy":"ONEDATA","dateModified":"2021-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F92A8A4B-FAF3-4EBB-E053-731AD00A3708","beginDate":"2023-04-12","endDate":null,"createdBy":"JKNABLE","dateCreated":"2023-04-12","modifiedBy":"JKNABLE","dateModified":"2023-04-12","deletedIndicator":"No"},{"value":"FNCLCC, Grade 1","valueDescription":null,"ValueMeaning":{"publicId":"7653575","version":"1","preferredName":"FNCLCC Sarcoma Grade 1","longName":"7653575","preferredDefinition":"A sarcoma with a total score of 2 or 3 according to the FNCLCC guidelines.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma G1","conceptCode":"C9024","definition":"A sarcoma with a total score of 2 or 3 according to the FNCLCC guidelines.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C223A6E9-64DD-1AAB-E053-4EBD850A3FD4","latestVersionIndicator":"Yes","beginDate":"2021-05-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-05-12","modifiedBy":"ONEDATA","dateModified":"2021-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F92A8A4B-FAF4-4EBB-E053-731AD00A3708","beginDate":"2023-04-12","endDate":null,"createdBy":"JKNABLE","dateCreated":"2023-04-12","modifiedBy":"JKNABLE","dateModified":"2023-04-12","deletedIndicator":"No"},{"value":"FNCLCC, Grade 3","valueDescription":null,"ValueMeaning":{"publicId":"6102879","version":"1","preferredName":"FNCLCC Sarcoma Grade 3","longName":"6102879","preferredDefinition":"A sarcoma with a total score of 6 or higher according to the FNCLCC guidelines.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma G3","conceptCode":"C9029","definition":"A sarcoma with a total score of 6 or higher according to the FNCLCC guidelines.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66B7CD99-D0CF-0E20-E053-F662850A9CB0","latestVersionIndicator":"Yes","beginDate":"2018-03-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-03-06","modifiedBy":"ONEDATA","dateModified":"2018-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F92A8A4B-FAF5-4EBB-E053-731AD00A3708","beginDate":"2023-04-12","endDate":null,"createdBy":"JKNABLE","dateCreated":"2023-04-12","modifiedBy":"JKNABLE","dateModified":"2023-04-12","deletedIndicator":"No"},{"value":"FNCLCC, Grade 2","valueDescription":null,"ValueMeaning":{"publicId":"6102881","version":"1","preferredName":"FNCLCC Sarcoma Grade 2","longName":"6102881","preferredDefinition":"A sarcoma with a total score of 4 or 5 according to the FNCLCC guidelines.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma G2","conceptCode":"C9028","definition":"A sarcoma with a total score of 4 or 5 according to the FNCLCC guidelines.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66B7CD99-D0F5-0E20-E053-F662850A9CB0","latestVersionIndicator":"Yes","beginDate":"2018-03-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-03-06","modifiedBy":"ONEDATA","dateModified":"2018-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F92A8A4B-FAF6-4EBB-E053-731AD00A3708","beginDate":"2023-04-12","endDate":null,"createdBy":"JKNABLE","dateCreated":"2023-04-12","modifiedBy":"JKNABLE","dateModified":"2023-04-12","deletedIndicator":"No"},{"value":"Unknown","valueDescription":null,"ValueMeaning":{"publicId":"5682953","version":"1","preferredName":"Unknown","longName":"5682953","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4645-0FC6-0802-E053-F662850AB305","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F92A8A4B-FAF7-4EBB-E053-731AD00A3708","beginDate":"2023-04-12","endDate":null,"createdBy":"JKNABLE","dateCreated":"2023-04-12","modifiedBy":"JKNABLE","dateModified":"2023-04-12","deletedIndicator":"No"},{"value":"Not Reported","valueDescription":null,"ValueMeaning":{"publicId":"5612322","version":"1","preferredName":"Not Reported","longName":"5612322v1.00","preferredDefinition":"Not provided or available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45340835-3B00-7C78-E053-F662850A44F9","latestVersionIndicator":"Yes","beginDate":"2017-01-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-01-03","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"10/10/23 changed Long Name from \"Not Stated\" to match NCIt Preferred name and current caDSR concept Long Name of \"Not Reported\" per Brenda.Janice . LS","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F92A8A4B-FAF8-4EBB-E053-731AD00A3708","beginDate":"2023-04-12","endDate":null,"createdBy":"JKNABLE","dateCreated":"2023-04-12","modifiedBy":"JKNABLE","dateModified":"2023-04-12","deletedIndicator":"No"},{"value":"Broders, Grade 1","valueDescription":null,"ValueMeaning":{"publicId":"13750988","version":"1","preferredName":"Broder's Grade 1","longName":"13750988v1.00","preferredDefinition":"Well-differentiated tumor (0-25% undifferentiated cells).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Broder's Grade 1","conceptCode":"C198136","definition":"Well-differentiated tumor (0-25% undifferentiated cells).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEA6FEF-8CA5-1478-E053-731AD00AB880","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEA6FEF-8CA9-1478-E053-731AD00AB880","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Broders, Grade 2","valueDescription":null,"ValueMeaning":{"publicId":"13750989","version":"1","preferredName":"Broder's Grade 2","longName":"13750989v1.00","preferredDefinition":"Moderately-differentiated tumor (25-50% undifferentiated cells).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Broder's Grade 2","conceptCode":"C198138","definition":"Moderately-differentiated tumor (25-50% undifferentiated cells).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEA6FEF-8CA6-1478-E053-731AD00AB880","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEA6FEF-8CAA-1478-E053-731AD00AB880","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Broders, Grade 3","valueDescription":null,"ValueMeaning":{"publicId":"13750990","version":"1","preferredName":"Broder's Grade 3","longName":"13750990v1.00","preferredDefinition":"Poorly-differentiated tumor (50-75% undifferentiated cells).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Broder's Grade 3","conceptCode":"C198140","definition":"Poorly-differentiated tumor (50-75% undifferentiated cells).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEA6FEF-8CA7-1478-E053-731AD00AB880","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEA6FEF-8CAB-1478-E053-731AD00AB880","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Broders, Grade 4","valueDescription":null,"ValueMeaning":{"publicId":"13750991","version":"1","preferredName":"Broder's Grade 4","longName":"13750991v1.00","preferredDefinition":"Anaplastic tumor (75-100% undifferentiated cells).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Broder's Grade 4","conceptCode":"C198141","definition":"Anaplastic tumor (75-100% undifferentiated cells).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEA6FEF-8CA8-1478-E053-731AD00AB880","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEA6FEF-8CAC-1478-E053-731AD00AB880","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Brynes. Grade 1","valueDescription":null,"ValueMeaning":{"publicId":"13750992","version":"1","preferredName":"Bryne's Grade 1","longName":"13750992v1.00","preferredDefinition":"Total score 4-8 (well-differentiated tumor).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bryne's Grade 1","conceptCode":"C198144","definition":"Total score 4-8 (well-differentiated tumor).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEA75AC-646B-1523-E053-731AD00ABA9B","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEA75AC-646E-1523-E053-731AD00ABA9B","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Brynes. Grade 2","valueDescription":null,"ValueMeaning":{"publicId":"13750993","version":"1","preferredName":"Bryne's Grade 2","longName":"13750993v1.00","preferredDefinition":"Total score 9-12 (moderately-differentiated tumor).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bryne's Grade 2","conceptCode":"C198145","definition":"Total score 9-12 (moderately-differentiated tumor).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEA75AC-646C-1523-E053-731AD00ABA9B","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEA75AC-646F-1523-E053-731AD00ABA9B","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"Brynes. Grade 3","valueDescription":null,"ValueMeaning":{"publicId":"13750994","version":"1","preferredName":"Bryne's Grade 3","longName":"13750994v1.00","preferredDefinition":"Total score 13-16 (poorly-differentiated tumor).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bryne's Grade 3","conceptCode":"C198146","definition":"Total score 13-16 (poorly-differentiated tumor).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCEA75AC-646D-1523-E053-731AD00ABA9B","latestVersionIndicator":"Yes","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FCEA75AC-6470-1523-E053-731AD00ABA9B","beginDate":"2023-05-30","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-05-30","modifiedBy":"COLBERTM","dateModified":"2023-05-30","deletedIndicator":"No"},{"value":"System NOS, GX","valueDescription":null,"ValueMeaning":{"publicId":"10987209","version":"1","preferredName":"Grade X","longName":"10987209v1.00","preferredDefinition":"A morphologic qualifier indicating that the grade of a neoplasm cannot be assessed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade X","conceptCode":"C113730","definition":"A morphologic qualifier indicating that the grade of a neoplasm cannot be assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5892CDB-26A1-62C6-E053-731AD00A9902","latestVersionIndicator":"Yes","beginDate":"2022-08-05","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2022-08-05","modifiedBy":"RAGUNATHANU","dateModified":"2022-08-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD8F0B4C-2BD7-5D58-E053-731AD00A18DC","beginDate":"2023-06-07","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-06-07","modifiedBy":"COLBERTM","dateModified":"2023-06-07","deletedIndicator":"No"},{"value":"System NOS, G1","valueDescription":null,"ValueMeaning":{"publicId":"3270009","version":"1","preferredName":"Grade 1","longName":"3270009","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 1","conceptCode":"C28077","definition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC4B0802-7E3A-C755-E040-BB89AD43108E","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD8F0B4C-2BD8-5D58-E053-731AD00A18DC","beginDate":"2023-06-07","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-06-07","modifiedBy":"COLBERTM","dateModified":"2023-06-07","deletedIndicator":"No"},{"value":"System NOS, G2","valueDescription":null,"ValueMeaning":{"publicId":"5622672","version":"1","preferredName":"Grade 2","longName":"5622672","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is moderately differentiated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 2","conceptCode":"C28078","definition":"A morphologic qualifier indicating that a cancerous lesion is moderately differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45D39BCC-34F2-6918-E053-F662850A008A","latestVersionIndicator":"Yes","beginDate":"2017-01-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD8F0B4C-2BD9-5D58-E053-731AD00A18DC","beginDate":"2023-06-07","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-06-07","modifiedBy":"COLBERTM","dateModified":"2023-06-07","deletedIndicator":"No"},{"value":"System NOS, G3","valueDescription":null,"ValueMeaning":{"publicId":"5622671","version":"1","preferredName":"Grade 3","longName":"5622671","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3","conceptCode":"C28079","definition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45D39BCC-34D0-6918-E053-F662850A008A","latestVersionIndicator":"Yes","beginDate":"2017-01-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD8F0B4C-2BDA-5D58-E053-731AD00A18DC","beginDate":"2023-06-07","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-06-07","modifiedBy":"COLBERTM","dateModified":"2023-06-07","deletedIndicator":"No"},{"value":"System NOS, G4","valueDescription":null,"ValueMeaning":{"publicId":"3270006","version":"1","preferredName":"Grade 4","longName":"3270006","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 4","conceptCode":"C28082","definition":"A morphologic qualifier indicating that a cancerous lesion is undifferentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC4B0802-7DD1-C755-E040-BB89AD43108E","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD8F0B4C-2BDB-5D58-E053-731AD00A18DC","beginDate":"2023-06-07","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-06-07","modifiedBy":"COLBERTM","dateModified":"2023-06-07","deletedIndicator":"No"},{"value":"INPC, Undifferentiated","valueDescription":null,"ValueMeaning":{"publicId":"13812816","version":"1","preferredName":"INPC Undifferentiated","longName":"13812816v1.00","preferredDefinition":"A neuroblastoma characterized by the absence of differentiating neuroblasts._A classification system established by adopting the original system proposed by Shimada with subsequent revisions. The INPC distinguishes favorable and unfavorable histology groups.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated Neuroblastoma","conceptCode":"C42046","definition":"A neuroblastoma characterized by the absence of differentiating neuroblasts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"International Neuroblastoma Pathology Classification","conceptCode":"C102562","definition":"A classification system established by adopting the original system proposed by Shimada with subsequent revisions. The INPC distinguishes favorable and unfavorable histology groups.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD8F494C-0BCD-6561-E053-731AD00A90E3","latestVersionIndicator":"Yes","beginDate":"2023-06-07","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-06-07","modifiedBy":"COLBERTM","dateModified":"2023-06-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD8F494C-0BD0-6561-E053-731AD00A90E3","beginDate":"2023-06-07","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-06-07","modifiedBy":"COLBERTM","dateModified":"2023-06-07","deletedIndicator":"No"},{"value":"INPC, Poorly Differentiated","valueDescription":null,"ValueMeaning":{"publicId":"13812817","version":"1","preferredName":"INPC Poorly Differentiated","longName":"13812817v1.00","preferredDefinition":"A neuroblastoma in which the differentiating neuroblasts constitute less than five-percent of the tumor cells._A classification system established by adopting the original system proposed by Shimada with subsequent revisions. The INPC distinguishes favorable and unfavorable histology groups.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Poorly Differentiated Neuroblastoma","conceptCode":"C42047","definition":"A neuroblastoma in which the differentiating neuroblasts constitute less than five-percent of the tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"International Neuroblastoma Pathology Classification","conceptCode":"C102562","definition":"A classification system established by adopting the original system proposed by Shimada with subsequent revisions. The INPC distinguishes favorable and unfavorable histology groups.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD8F494C-0BCE-6561-E053-731AD00A90E3","latestVersionIndicator":"Yes","beginDate":"2023-06-07","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-06-07","modifiedBy":"COLBERTM","dateModified":"2023-06-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD8F494C-0BD1-6561-E053-731AD00A90E3","beginDate":"2023-06-07","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-06-07","modifiedBy":"COLBERTM","dateModified":"2023-06-07","deletedIndicator":"No"},{"value":"INPC, Differentiating","valueDescription":null,"ValueMeaning":{"publicId":"13812818","version":"1","preferredName":"INPC Differentiating","longName":"13812818v1.00","preferredDefinition":"A neuroblastoma in which the differentiating neuroblasts constitute more than five-percent of the tumor cells._A classification system established by adopting the original system proposed by Shimada with subsequent revisions. The INPC distinguishes favorable and unfavorable histology groups.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Differentiating Neuroblastoma","conceptCode":"C42048","definition":"A neuroblastoma in which the differentiating neuroblasts constitute more than five-percent of the tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"International Neuroblastoma Pathology Classification","conceptCode":"C102562","definition":"A classification system established by adopting the original system proposed by Shimada with subsequent revisions. The INPC distinguishes favorable and unfavorable histology groups.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD8F494C-0BCF-6561-E053-731AD00A90E3","latestVersionIndicator":"Yes","beginDate":"2023-06-07","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-06-07","modifiedBy":"COLBERTM","dateModified":"2023-06-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD8F494C-0BD2-6561-E053-731AD00A90E3","beginDate":"2023-06-07","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-06-07","modifiedBy":"COLBERTM","dateModified":"2023-06-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435018","version":"1","preferredName":"Clinical or Research Activity","preferredDefinition":"Any specific activity undertaken during the course of a clinical study or research protocol.","longName":"C16203","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831E-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"13336619","version":"1","preferredName":"Histologic Grade Type","preferredDefinition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems._Something distinguishable as an identifiable class based on common qualities.","longName":"13336619v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8FF2077-56CD-01ED-E053-731AD00A5B05","latestVersionIndicator":"Yes","beginDate":"2023-04-10","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-04-10","modifiedBy":"COLBERTM","dateModified":"2023-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"PCDC:Pediatric Cancer Data Commons","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8FF2077-56CE-01ED-E053-731AD00A5B05","latestVersionIndicator":"Yes","beginDate":"2023-04-10","endDate":null,"createdBy":"COLBERTM","dateCreated":"2023-04-10","modifiedBy":"FINCHAMB","dateModified":"2023-11-11","changeDescription":null,"administrativeNotes":"11/11/23 Released per PCDC-U of Chicago/Mei Li. BF;4/10/23 Created per PCDC submission template. mr","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"12173174","version":"1","longName":"PCDC Aggregated Dictionary","context":"Pediatric Cancer","ClassificationSchemeItems":[{"publicId":"12173178","version":"1","longName":"Disease Attributes","context":"Pediatric Cancer"},{"publicId":"12173199","version":"1","longName":"Histology","context":"Pediatric Cancer"}]},{"publicId":"13954630","version":"1","longName":"All Pediatric Core CDEs","context":"Pediatric Cancer","ClassificationSchemeItems":[{"publicId":"14599262","version":"1","longName":"Specimen","context":"Pediatric Cancer"}]}],"AlternateNames":[{"name":"HISTOLOGY_GRADE","type":"PCDC Alt Name","context":"Pediatric Cancer"},{"name":"Histology Grade","type":"Ped Cancer Alt Name","context":"Pediatric Cancer"}],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Histology Grade","url":null,"context":"Pediatric Cancer"},{"name":"Ped Cancer Instruction","type":"Instructions","description":"Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","url":null,"context":"Pediatric Cancer"}],"origin":"PCDC:Pediatric Cancer Data Commons","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9B6AE2E-EEBD-20B3-E053-731AD00AA622","latestVersionIndicator":"Yes","beginDate":"2023-04-19","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-19","modifiedBy":"JKNABLE","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":"2/22/24 Added Ped Core Alts, CSI per PCDC/MW recommendations. mr; 11/11/23 Released per PCDC-U of Chicago/Mei Li. BF;4/19/23 Curated for PCDC. BF","unresolvedIssues":null,"deletedIndicator":"No"}}